TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03758846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-motor exergaming
Description: Participants undergo 6 weeks of cognitive-motor exergaming using Wii-fit Nintendo. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional balance Training
Description: Participants undergo 6 weeks of conventional exercise training. The 6 weeks included a total of 20 session distributed in the following manner: 5 sessions/week for 1-2 week, 3 session/week for 3-4 week, 2 sessions/week for 5-6 week. Each session lasted for about 90 minutes with rests included.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Therapy for Stroke
Description: Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two physical therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Therapy for Older adults
Description: Participants will receive therapy using the Just Dance using the commercially available Kinect gaming system (Microsoft Inc, Redmond, WA, USA. Each song involves repetitive action for each dance step (at least 20 repetitions over the entire song) and visual cues on the screen (a stick figure at the bottom right) indicating the upcoming dance step. Participant's playing the game to reduce risk of exercise related adverse effects. Participants will dance on 10 songs starting from a slow-pace progressing to a medium pace (each max 5 minutes long). Participants will receive 5 minutes rest after playing on each song. This will be conducted by two therapists.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home education for Older adults
Description: Participants will receive a one-hour education on conventional physical exercises.
Study: NCT01890031

Intervention type: OTHER
Group type: OTHER
Intervention: Interactive Cholesterol Advisory Tool
Description: using the virtual clinician computer program for cholesterol information and education.

Intervention type: OTHER
Group type: OTHER
Intervention: Interactive Cholesterol Advisory Tool
Description: using the virtual clinician computer program for cholesterol information and education.

Intervention type: OTHER
Group type: OTHER
Intervention: Interactive Cholesterol Advisory Tool
Description: using the virtual clinician computer program for cholesterol information and education.

Intervention type: OTHER
Group type: OTHER
Intervention: Study physician visits
Description: In-person individual visits with a study physician to give information on cholesterol

Intervention type: OTHER
Group type: OTHER
Intervention: Study physician visits
Description: In-person individual visits with a study physician to give information on cholesterol

Intervention type: OTHER
Group type: OTHER
Intervention: Study physician visits
Description: In-person individual visits with a study physician to give information on cholesterol
Study: NCT04021745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-based mindful eating
Description: This is a mindful eating smartphone application comprised of twenty-eight modules of 10-15 minutes each designed to teach mindfulness for binge eating. The feature that is being tested will ask individuals to do a mental exercise when they're craving and will measure their satisfaction related to the experience.
Study: NCT02578251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Study: NCT03749239

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen protein
Description: Collagen protein
Study: NCT04586257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: While patients in the prone position, 1.4-5.1 MHz low-frequency probe (C5-1s convex transducer) will be first placed in a longitudinal orientation in the midline to identify the spinous process of at the appropriate lumbar level, then it will be scanned laterally about 2-3 cm until visualization of the paraspinal muscles and the transverse process at the same time. After standard sterilization, a 21-G short bevel nerve block needle will be advanced in a cephalad-to-caudal direction, in-plane under real- time ultrasound guidance, through skin, subcutaneous tissue, and erector spinae muscles until reaching the transverse process. After negative aspiration of blood or cerebral spinal fluid, a small volume of local anesthetic was injected to confirm the position of the needle tip between the erector spinae muscles and the transverse process. A total of 20 ml of 0.0.25% plain bupivacaine will be incrementally injected with intermittent negative aspiration on each side.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Throacolumbar interfacial plane block
Description: USG-guided TLIP block will be performed using a high-frequency linear probe while the patient in prone position. The probe will be covered with sterile sheath positioned transversally in a midline position at approximately the level of the 3rd lumbar vertebra (L3). The corresponding spinous process and interspinal muscles will be identified, and the probe will be slid laterally to identify the multifidus (MF) muscle and longissimus (LG) muscle. Sliding the probe from midline to laterally helps in the correct identification of various muscles. After identifying the muscles, TLIP block will be performed aseptically on both sides of L3 vertebra. Under ultrasound guidance, an insulated echogenic needle will be inserted in-plane in a lateral to medial orientation in-plane USG guided through the belly of LG toward the MF. When needle reach deep to middle of MF/LG interface, 20 ml 0.25% bupivacaine will be injected after negative aspiration. The block will be administered bilaterally.
Study: NCT00480727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Halo pin re-tensioning
Description: Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Re-tensioning
Description: Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
Study: NCT00829244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GONAL f® prefilled pen
Description: GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GONAL f® prefilled pen
Description: GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
Study: NCT00877656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HuMax-CD4
Description: Active treatment
Study: NCT00894881

Intervention type: PROCEDURE
Intervention: Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]
Description: resting energy expenditure (REE).
Study: NCT04559724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indego Therapy
Description: Indego Therapy consists of 15 + 2 sessions of Indego - Therapy, each lasting 30 minutes for a maximum of 6 weeks. All the device parameters such as step height (knee and hip), step length, step cycle speed, single and bilateral assistance are customizable. The use of aids during Idego-Therapy is allowed if needed. The Indego specialist should initially be positioned behind the patient, checking the exoskeleton and patient's gait pattern. The supervision of an assistant placed on the patient's healthy side is recommended in the first sessions in order to ensure greater safety to the patient. Constant supervision should be provided by Indego specialist during the whole treatment.
Study: NCT03441048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lintuzumab-Ac-225
Description: Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of relapsed/refractory acute myeloid leukemia.
Study: NCT05322005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial meniscectomy
Description: Arthroscopic procedure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condrotide® (polynucleotides gel: class III medical device)
Description: Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Condrotide® (polynucleotides gel: class III medical device)
Description: Condrotide® Polynucleotide gel is a joint lubricating and viscosizing agent, given by intraarticular and intra-meniscal injection
Study: NCT02135133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 150 mg BID Oral Daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
Study: NCT03782493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Enhanced Milieu Teaching-Sentence Focus
Description: Caregivers in the treatment group (EMT-SF) will receive 66 EMT-SF intervention sessions at home over 18 months. They will be taught the intervention strategies using a manualized protocol (Teach-Model-Coach-Review).
Study: NCT00496119

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: 70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: 70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photon Beam Therapy
Description: Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
Study: NCT06192550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound Matrix™ System
Description: Study subjects will be treated with the Profound Matrix System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound Matrix™ System
Description: Study subjects will be treated with the Profound Matrix System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Profound Matrix™ System
Description: Study subjects will be treated with the Profound Matrix System
Study: NCT04344912

Intervention type: OTHER
Intervention: Data collection
Description: Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies

Intervention type: OTHER
Intervention: Data collection
Description: Diagnostic and prognostic evaluation of cardiac patients hospitalized in CCU during the COVID-19 outbreak; patient's immune status regarding the presence of SARS-CoV-2 specific antibodies
Study: NCT02166463

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT04278781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-120
Description: AG-120 500 mg orally once daily days 1-28 of a 28-day cycle
Study: NCT02574715

Intervention type: DRUG
Intervention: Levonorgestrel (Jaydess, BAY86-5028)
Description: Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
Study: NCT02172196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Study: NCT04249596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tianeptine Sodium
Description: At baseline, and following 8 weeks of treatment with tianeptine(12.5 mg, 3x daily), participants will be assessed in a number of procedures to evaluate their emotional and physical pain state and pain stimulus response and the relationship of such states/responses to endogenous opioid signaling. To further assess emotional pain, participants will also undergo fMRI while performing a validated social rejection and social acceptance paradigm known to induce endogenous opioid release in control subjects and blunted release in MDD. Examining both rejection and acceptance is important because the MOR system regulates both social distress and social reward in animals and humans, and tianeptine may also act on abnormal MOR-mediated responses to social acceptance in MDD. Likewise, a second fMRI scan will be used to explore physical pain response using an established thermal pain sensitivity task. The protocol at Stanford University will not include pain testing or imaging studies.
Study: NCT02900053

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS for transcranial Direct-Current Stimulation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tDCS
Description: Placebo tDCS for transcranial Direct-Current Stimulation
Study: NCT01767610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized fenofibrate 160mg
Study: NCT03441048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells.
Study: NCT03368001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SENSE Theatre
Description: SENSE Theatre is a peer-mediated, theatre-based intervention targeting social competence in youth with autism spectrum disorder. The 40 hour intervention is comprised of 10 sessions in which trained typically peers are paired with children with autism spectrum disorder (ASD).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tackling Teenage Together
Description: The Tackling Teenage Together is a psychosocial and sexual education program developed for youth with ASD. It is comprised of 10 sessions.
Study: NCT04074499

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention.

Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention.
Study: NCT04143646

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based prevention program
Description: Telemetric control of risk factors, e-learning, contacts by e-mails/apps. If no response telephone calls.~In a substudy evaluation of disclosure of genetic risk.
Study: NCT03425526

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes
Description: Given IV
Study: NCT00869570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Phase II: 2 x 825 mg/m2 per day (during 5 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Phase II: 1 x 400 mg per day (during 5 weeks)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
Study: NCT03030950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: to give normal saline to the other group as a placebo
Study: NCT03514199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet
Description: Recommendations: ingest whole grains; three or more servings/day (various fresh fruits/vegetables); three or more servings/week of fish or seafood; white meat to red and processed meat (red meat to one serving or less/day); oilseed mix - 30g/day (nuts: 15g/day, almonds: 7.5g/day, hazelnuts: 7.5g/day); extra virgin olive oil (30ml/day: 2 soup spoons/day) as the main source of fat in the salads; two or more servings per week of sofrito; two servings/day of low-fat dairy products; limit to one serving/week the intake of fatty and cured cheeses; recommendation of 7 glasses per week of red wine (recommendation for habitual drinkers): 1 cup/day of 100ml for women and 1-2 cups/day of 150ml for men; limit to one serving/week the intake of chocolate with more than 50% cocoa.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat diet
Description: Recommendations: choose grilled, cooked, baked or soaked preparations; avoid frying (sweet or salty); avoid excess fat in the preparations and season the foods with herbs at will (marjoram, basil, oregano, onion, green seasoning, sweet pepper, sage, etc.); avoid frequent ingestion of sausages such as ham, turkey breast, among others; avoid eating fatty meats and strip the skin of poultry before preparation; avoid eating sweets and fatty foods; avoid ingesting bakery products, such as leafy, tart, savory pasta.
Study: NCT01767610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin Ca 2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: micronized fenofibrate 160mg plus pitavastatin Ca 2mg
Study: NCT04034836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scalp blocks with ropivacaine plus parecoxib
Description: Scalp blocks with ropivacaine 0.75% wt/vol, 20ml, plus 10 mg parecoxib (diluted in 2 mL NS) with epinephrine at 1:200,000 (5 ug/mL) and i.v. saline 2ml;An independent researcher will prepare the study solution in a separate operating room. The study solutions with syringes (50-ml) for the scalp blocks and syringes (5-ml) for intravenous injection are prepared and numbered with a 23-gauge needle by an independent researcher, after opening the envelope containing the allocation of treatment. After induction, the assigned solutions will be injected subcutaneously or intravenously separately by the anesthesiologist. The scalp blocks will be performed along the lines of the technique previously described by Pinosky et al. The following nerves were blocked bilaterally: the supraorbital and supratrochlear nerves; the zygomatico-temporal nerves; the auriculotemporal nerves; the postauricular branches of the greater auricular nerves; the greater, lesser, and third occipital nerves.
Study: NCT02166463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT03474107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinflunine
Description: Intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous infusion
Study: NCT02015598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbocysteine
Description: carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure
Description: Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
Study: NCT04089605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone implant
Description: intravitreal dexamethasone implant injections in vitrectomized patients with DME

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal ranibizumab injections in vitrectomized patients with DME
Study: NCT02711761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheterization
Description: 15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheterization
Description: 15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: central venous catheterization
Description: 15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.~17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.~20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm.
Study: NCT02531035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin, once daily, before the first meal of the day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, before the first meal of the day